NASDAQ Soins de santé Biotechnologie SLXNW

Silexion Therapeutics Ltd.

$ 0.04 75.40 %

Silexion Therapeutics LTD is a biopharmaceutical company focused on the discovery and development of RNA interference (RNAi)-based therapies and their delivery systems, specifically targeting aggressive solid tumors. The firm utilizes its proprietary LODER delivery platform for the treatment of these malignant growths. Its pipeline features SiG12D-LODER, which has successfully completed preclinical investigations and an open-label Phase I clinical trial for pancreatic cancer. Additionally, the company is advancing Prostate-LODER through preclinical studies for prostate cancer, and GBM-LODER, also in preclinical stages, to address Glioblastoma Multiforme, a severe primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.

CEO: Ilan Hadar - https://silexion.com

Summary 30-Y Financials Dividend Analyst Historique indicateurs Possession / Senat
Price objectif

-

Recommandation

-

DCF

$ 35.88

Loading data...

SLXNW vs S&P500

Loading data...

No data available.

Quick ratio

1.00

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

0.00

may indicate that the company is undervalued or has poor growth prospects.

EPS

0.00

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-516.87 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

1 448.83 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

4.59

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

1.50

means it relies more on debt, which can increase financial risk.

Free cash flow per share

-37.19

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
2 indicates worrying financial health
Altman score
-24.71 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.59 indicates that the company has a moderate ability to cover its short-term debts with its cash
Debt Ratio
0.09 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.